

Javier Loricera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9457246/publications.pdf>

Version: 2024-02-01

29
papers

1,305
citations

430874

18
h-index

501196

28
g-index

31
all docs

31
docs citations

31
times ranked

1456
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients. <i>Arthritis and Rheumatology</i> , 2017, 69, 668-675.	5.6	129
2	Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 22-27.	3.4	123
3	Henoch-Schönlein Purpura in Northern Spain. <i>Medicine (United States)</i> , 2014, 93, 106-113.	1.0	117
4	Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 717-723.	3.4	114
5	Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study. <i>Rheumatology</i> , 2018, 57, 856-864.	1.9	88
6	Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. <i>American Journal of Ophthalmology</i> , 2019, 200, 85-94.	3.3	81
7	Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 95-101.	3.4	77
8	Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 126-135.	3.4	66
9	Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 720-727.	3.4	63
10	The Spectrum of Paraneoplastic Cutaneous Vasculitis in a Defined Population. <i>Medicine (United States)</i> , 2014, 93, 53-60.	1.0	55
11	Tocilizumab in refractory aortitis: study on 16 patients and literature review. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S79-89.	0.8	55
12	Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease. <i>Ophthalmology</i> , 2018, 125, 1444-1451.	5.2	50
13	Urticarial Vasculitis in Northern Spain. <i>Medicine (United States)</i> , 2014, 93, 53-60.	1.0	46
14	18 F-FDG PET/CT in the follow-up of large-vessel vasculitis: A study of 37 consecutive patients. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 530-537.	3.4	45
15	Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases. <i>Rheumatology</i> , 2015, 54, 77-82.	1.9	42
16	Efficacy of Anti-IL6-Receptor Tocilizumab in Refractory Cystoid Macular Edema of Birdshot Retinochoroidopathy Report of Two Cases and Literature Review. <i>Ocular Immunology and Inflammation</i> , 2017, 25, 609-614.	1.8	33
17	Drug-associated Cutaneous Vasculitis: Study of 239 Patients from a Single Referral Center. <i>Journal of Rheumatology</i> , 2014, 41, 2201-2207.	2.0	32
18	Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S44-53.	0.8	32

#	ARTICLE	IF	CITATIONS
19	Biologic therapy in ANCA-negative vasculitis. <i>International Immunopharmacology</i> , 2015, 27, 213-219.	3.8	15
20	The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S34-S40.	0.8	10
21	Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110209.	2.7	7
22	A closer look at skin involvement in vasculitis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 186-187.	8.0	5
23	Safety of secukinumab for the treatment of active ankylosing spondylitis. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-8.	2.4	5
24	Prevalence and factors associated with osteoporosis and fragility fractures in patients with primary Sjögren syndrome. <i>Rheumatology International</i> , 2020, 40, 1259-1265.	3.0	4
25	Subclinical aortitis after starting nivolumab in a patient with metastatic melanoma. A case of drug-associated aortitis?. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 171.	0.8	3
26	Tocilizumab in giant cell arteritis: differences between the GACTA trial and a multicentre series of patients from the clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 112-119.	0.8	3
27	Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 69-75.	0.8	2
28	Histopathologic differences between cutaneous vasculitis associated with severe bacterial infection and cutaneous vasculitis secondary to other causes: study of 52 patients. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S93-7.	0.8	1
29	Digestive involvement in primary Sjögren's syndrome: analysis from the Sjögren registry. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 110-115.	0.8	0